St. Jude Medical Inc. (NYSE:STJ) received European regulatory approval for a cardiac ablation system used in procedures to destroy diseased tissue in patients with abnormal heart rhythms.
Receiving the CE Mark means that St. Jude may beginning marketing and selling its EnSite Contact Technology platform in the Eurpean Union. The system has not been cleared for U.S. sales.
